Faron Pharmaceuticals Ltd ("Faron" or the "Company") Faron Provides Update on Bexmarilimab Development Program Ahead of R&D Day Updated landmark analysis estimates nine-month overall survival rates were 70% for heavily pre-treated, late-stage cancer patients who benefited from treatment...
